DUPIXENT (dupilumab) has been listed on the Pharmaceutical Benefits Scheme (PBS) for patients aged 12 years and older with severe uncontrolled asthma caused by type 2 inflammation.
The biological therapy targets two key proteins - interleukins-4 and -13 - that drive the inflammatory response in the airways of 50% to 70% of patients with severe asthma.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Mar 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Mar 21
